44.97
전일 마감가:
$46.82
열려 있는:
$47
하루 거래량:
10,251
Relative Volume:
0.29
시가총액:
$275.00M
수익:
-
순이익/손실:
$-7.12M
주가수익비율:
-19.55
EPS:
-2.3
순현금흐름:
$-6.82M
1주 성능:
-3.25%
1개월 성능:
+40.88%
6개월 성능:
+8.47%
1년 성능:
+6,766%
Monopar Therapeutics Inc Stock (MNPR) Company Profile
명칭
Monopar Therapeutics Inc
전화
(847) 388-0349
주소
1000 SKOKIE BLVD SUITE 350, WILMETTE
MNPR을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
MNPR
Monopar Therapeutics Inc
|
44.97 | 286.31M | 0 | -7.12M | -6.82M | -2.30 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
469.65 | 121.28B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
563.10 | 60.96B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
328.81 | 42.77B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
591.99 | 36.21B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
291.47 | 32.08B | 3.81B | -644.79M | -669.77M | -6.24 |
Monopar Therapeutics Inc Stock (MNPR) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2025-07-07 | 개시 | Cantor Fitzgerald | Overweight |
2025-06-23 | 개시 | Chardan Capital Markets | Buy |
2025-03-19 | 재개 | Piper Sandler | Overweight |
2025-01-10 | 개시 | Piper Sandler | Overweight |
2024-10-11 | 개시 | Rodman & Renshaw | Buy |
2021-01-28 | 개시 | ROTH Capital | Buy |
모두보기
Monopar Therapeutics Inc 주식(MNPR)의 최신 뉴스
Monopar Therapeutics Inc. stock trend outlook and recovery path Free Growth Based Investment Plan Guidance - Newser
How strong is Monopar Therapeutics Inc. company’s balance sheetSuperior returns - jammulinksnews.com
What is the dividend policy of Monopar Therapeutics Inc. stockRetirement Planning Entry Points For Consistent Profits - jammulinksnews.com
Does Monopar Therapeutics Inc. stock perform well during market downturnsAchieve superior capital gains with smart trades - jammulinksnews.com
What are analysts’ price targets for Monopar Therapeutics Inc. in the next 12 monthsGet professional advice for market timing - jammulinksnews.com
How many analysts rate Monopar Therapeutics Inc. as a “Buy”Invest confidently with real-time data analysis - jammulinksnews.com
What is the risk reward ratio of investing in Monopar Therapeutics Inc. stockMaster stock selection with insider knowledge - jammulinksnews.com
When is the best time to buy Monopar Therapeutics Inc. stockLow Risk Trade Timing Signals - Newser
What makes Monopar Therapeutics Inc. stock price move sharplyFree Stock Selection with 300% Return - Newser
Why Monopar Therapeutics Inc. stock attracts strong analyst attentionFree Predictions - metal.it
What drives Monopar Therapeutics Inc. stock priceAccelerated capital growth - PrintWeekIndia
Is Monopar Therapeutics Inc. a good long term investmentPhenomenal returns - Autocar Professional
Does Monopar Therapeutics Inc. stock pay reliable dividendsConsistent double returns - jammulinksnews.com
What analysts say about Monopar Therapeutics Inc. stockFree Stock Index Interpretation - Autocar Professional
Monopar Therapeutics Inc. Stock Analysis and ForecastFree Investment Community - jammulinksnews.com
Long Term Trading Analysis for (MNPR) - news.stocktradersdaily.com
Is TBMCR a good long term investmentExplosive trading opportunities - jammulinksnews.com
Technical Analysis: Sreeleathers Limited (535601)Tremendous portfolio expansion - jammulinksnews.com
Is Siddhi Acquisition Corp. Debt Equity Composite Units a good long term investmentMarket-crushing profits - jammulinksnews.com
Las Vegas Sands Corp. Stock Analysis and ForecastMassive wealth growth - jammulinksnews.com
Best Stocks for Risk Averse Investors Market Trend Prediction ToolsFree Stock Chart Pattern Guide - jammulinksnews.com
Monopar Therapeutics Inc. (NASDAQ:MNPR) Receives Consensus Rating of “Moderate Buy” from Analysts - Defense World
Institutional Investors Control 29% of Monopar Therapeutics Inc. (NASDAQ:MNPR) and Were Rewarded Last Week After Stock Increased 23% - 富途牛牛
What analysts say about Monopar Therapeutics Inc. stock outlook5x Profit Potential - Newser
Monopar therapeutics director Tsuchimoto sells $356k in stock By Investing.com - Investing.com Canada
Monopar therapeutics director Starr sells $672k in stock By Investing.com - Investing.com Canada
Monopar Therapeutics Inc (MNPR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Monopar Therapeutics Inc 주식 (MNPR) 내부자 거래
내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
---|---|---|---|---|---|---|---|
STARR CHRISTOPHER M | Director |
Jul 14 '25 |
Sale |
40.00 |
16,800 |
672,020 |
5,173 |
Robinson Chandler | Chief Executive Officer |
Jul 14 '25 |
Sale |
40.00 |
16,800 |
672,020 |
73,472 |
자본화:
|
볼륨(24시간):